CERO Stock Overview
An immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CERo Therapeutics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.21 |
| 52 Week High | US$12.80 |
| 52 Week Low | US$0.17 |
| Beta | -0.40 |
| 11 Month Change | -40.12% |
| 3 Month Change | -85.04% |
| 1 Year Change | -98.04% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| CERO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.9% | 3.4% | -2.4% |
| 1Y | -98.0% | 17.1% | 17.5% |
Return vs Industry: CERO underperformed the US Biotechs industry which returned 14.9% over the past year.
Return vs Market: CERO underperformed the US Market which returned 19.8% over the past year.
Price Volatility
| CERO volatility | |
|---|---|
| CERO Average Weekly Movement | 20.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CERO's share price has been volatile over the past 3 months.
Volatility Over Time: CERO's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 9 | Brian Atwood | www.cero.bio |
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
CERo Therapeutics Holdings, Inc. Fundamentals Summary
| CERO fundamental statistics | |
|---|---|
| Market cap | US$2.95m |
| Earnings (TTM) | -US$1.83m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs CERO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CERO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.83m |
| Earnings | -US$1.83m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -10.1% |
How did CERO perform over the long term?
See historical performance and comparison